Literature DB >> 15277647

Deterioration of the auditory brainstem response in children with type 3 Gaucher disease.

Pauline E Campbell1, Chris M Harris, Ashok Vellodi.   

Abstract

Enzyme replacement therapy (ERT) has improved the quality of life in patients with Gaucher disease (GD). An emerging concern is whether ERT can also halt the neurologic progression in type 3 GD. The authors examined the auditory brainstem response (ABR) in eight children with type 3 GD undergoing high-dose ERT and found a consistent deterioration in ABR response. They conclude that ERT does not halt brainstem degeneration and that alternative therapies must be sought.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277647     DOI: 10.1212/01.wnl.0000130191.31669.48

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

2.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

3.  Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.

Authors:  J Cox-Brinkman; M J van Breemen; B T van Maldegem; L Bour; W E Donker; C E M Hollak; F A Wijburg; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2008-10-15       Impact factor: 4.982

4.  Randomized, controlled trial of miglustat in Gaucher's disease type 3.

Authors:  Raphael Schiffmann; Edmond J Fitzgibbon; Chris Harris; Catherine DeVile; Elin H Davies; Larry Abel; Ivo N van Schaik; William Benko; Margaret Timmons; Markus Ries; Ashok Vellodi
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

5.  Eye movement impairment recovery in a Gaucher patient treated with miglustat.

Authors:  Agostino Accardo; Stefano Pensiero; Giovanni Ciana; Fulvio Parentin; Bruno Bembi
Journal:  Neurol Res Int       Date:  2010-09-26

6.  Optimal therapy in Gaucher disease.

Authors:  Ozlem Goker-Alpan
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

7.  The saccadic and neurological deficits in type 3 Gaucher disease.

Authors:  William Benko; Markus Ries; Edythe A Wiggs; Roscoe O Brady; Raphael Schiffmann; Edmond J Fitzgibbon
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

8.  Previously unrecognized behavioral phenotype in Gaucher disease type 3.

Authors:  Magy Abdelwahab; Michael Potegal; Elsa G Shapiro; Igor Nestrasil
Journal:  Neurol Genet       Date:  2017-05-23

9.  Variation in cognitive function over time in Gaucher disease type 3.

Authors:  Alta M Steward; Edythe Wiggs; Taylor Lindstrom; Somto Ukwuani; Emory Ryan; Nahid Tayebi; Tamanna Roshan Lal; Grisel Lopez; Raphael Schiffmann; Ellen Sidransky
Journal:  Neurology       Date:  2019-11-12       Impact factor: 11.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.